Continuous glucose monitoring (CGM) | Medtronic (2024)

What is CGM?

CGM systems track glucose levels, every few minutes, 24/7 through a tiny sensor inserted under your skin, either on your abdomen or arm using an automatic inserter. The sensor measures your interstitial glucose level, which is the glucose found in the fluid between the cells. CGM therapy can be used with or without an insulin pump.^*

Play video

Predictive alerts - taking action sooner¹

What are the benefits of CGM?

A CGM system gives you a greater view of your sugar level trends. It can provide valuable information¹ at crucial points during the day, including before and during exercise, prior to driving, or in the middle of the night.

The CGM can provide this data to an integrated insulin pump or smart insulin pen to help provide actionable insights.

Whether you manage your diabetes with an insulin pump, insulin injections (MDI), oral medications, or through diet and exercise^¶, Medtronic offers CGM products and insulin pump systems that give you, your loved ones and healthcare professionals the insights to stay ahead of diabetes and help you live life on your terms.

CGM device systems

By connecting the CGM to a smart insulin pen or insulin pump, you allow technology to help do more of the thinking, remembering, and acting, when it comes to managing diabetes.

Talk to a diabetes therapy consultant

To request a free insurance coverage check and learn more about your eligibility and potential out-of-pocket costs, please complete the form below or call 1-800-646-4633, and one of our Diabetes Therapy consultants will be happy to assist you.

Standalone CGMFinancial support programs

¶ Access depends upon health plan design.
1 The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices and not on values provided by the system.
2 Grunberger G, Bailey TS, Cohen AJ, et al; and AACE Insulin Pump Management Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010;16(4):746-762.
∆ Smart devices sold separately. For a list of compatible devices, refer to user guide.

*Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.

** Assumes 4 injections per day for 30 days and one infusion set change every seven days.

Important Safety Information: Guardian^™ Connect CGM System
The Guardian^™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and http://www.medtronicdiabetes.com/important-safety-information.

Important Safety Information: MiniMed^™ 780G System With SmartGuard^™ Technology With Guardian^™ 4 Sensor
The MiniMed^™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed^™ 780G system includes SmartGuard^™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed^™ 780G system consists of the following devices: MiniMed^™ 780G insulin pump, the Guardian^™ 4 transmitter, the Guardian^™ 4 sensor, One-press serter, the Accu-Chek^™ Guide Link blood glucose meter, and the Accu-Chek^™ Guide test strips. The system requires a prescription from a healthcare professional.

The Guardian^™ 4 sensor is intended for use with the MiniMed^™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian^™ 4 sensor is indicated for up to seven days of continuous use.

The Guardian^™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed^™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian^™ 4 sensor. The Guardian^™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian^™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

WARNING: Do not use the SmartGuard^™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard^™ feature.

WARNING: Do not use the MiniMed^™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed^™ 780G system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard^™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed^™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library